Inventor · disambiguated record
Brandon James Turunen
Also filed as: TURUNEN BRANDON · TURUNEN BRANDON JAMES
0 granted patents·10 pending applications·0 citations·filing 2018–2024
Top patents by PatentIndex Score
10 records- 0165US2025051479A1Cytotoxicity targeting chimeras for cxcr3-expressing cellsGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 0264US2025154288A1Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cellsGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 0364US2025057827A1Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cellsGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 0463US2025049932A1Cytotoxicity targeting chimeras for folate receptor-expressing cellsGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 0563US2025064947A1Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cellsGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 0661US2025057958A1Cytotoxicity targeting chimeras for ccr2-expressing cellsGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 0758US2021379044A1Non peptidic heterobivalent molecules for treating inflammatory diseasesGLAXOSMITHKLINE IP DEV LTD·Filed 2021·Application pending·0 cites
- 0852US2025136722A1Cytotoxicity targeting chimerasGLAXOSMITHKLINE IP DEV LTD·Filed 2022·Application pending·0 cites
- 0942US2019336489A1Non peptide heterobivalent molecules for treating inflammatory diseasesGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 1041US2025101008A1Heterobifunctional molecules for binding ccr2 and methods of treating medical conditions using sameSOLU THERAPEUTICS INC·Filed 2024·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Brandon James Turunen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →